Entera Bio vs VivoSim Labs
ENTX and VIVS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENTX and VIVS compare
Entera Bio is the larger company, worth 285 times as much as VivoSim Labs ($538M against $1.9M).
VivoSim Labs grew revenue faster over the last twelve months (−3.6% versus −100% for Entera Bio).
Entera Bio scores higher on the StockData Score (8 against 5 for VivoSim Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENTX | VIVS |
|---|---|---|
| Size and price | ||
| Market cap | $538M | $1.9M |
| Share price | $3.11 | $0.127 |
| Change, 1 year | 6.9% | −94.4% |
| Change, 5 years | −11.6% | −99.8% |
| Beta (5Y) | 0.62 | 1.50 |
| Employees | 20 | 15 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 14.0× |
| P/B | 2.0× | 0.3× (better) |
| FCF yield | −2.9% (better) | −545% |
| Growth | ||
| Revenue growth (TTM) | −100% | −3.6% (better) |
| Revenue growth, 5Y average | −35.1% | – |
| EPS growth, 5Y average | −17.9% | – |
| Profitability | ||
| Operating margin | – | −8898% |
| Net margin | – | −7606% |
| FCF margin | – | −7619% |
| Return on equity | −20.3% (better) | −144% |
| Return on invested capital | −193% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −1001.0× |
| Current ratio | 128.41 (better) | 3.50 |
| Altman Z-score | 117.35 (better) | −53.22 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% (better) | −159% |
| Shareholder yield | 0.00% (better) | −159% |
| Ownership | ||
| Held by institutions | 6.2% | 0.70% |
| Held by insiders | 11.3% | 45.0% |
| Insider net buying, 12 months | $141K (better) | $2.8K |
| Short interest, % of float | 4.6% | 8.0% |
Go deeper
- ENTX stock overview
- ENTX income statement
- ENTX valuation and score
- VIVS stock overview
- VIVS income statement
- VIVS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.